Jane Street
CERE

Jane Street’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Jane Street’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-269,948
Closed -$11M – 10712
2024
Q2 		$11M Buy
+269,948
New +$11.2M ﹤0.01% 1932
2024
Q1 		– Sell
-253,424
Closed -$10.6M – 10307
2023
Q4 		$10.7M Buy
253,424
+212,098
+513% +$6.09M ﹤0.01% 1864
2023
Q3 		$902K Sell
41,326
-93,864
-69% -$2.35M ﹤0.01% 5331
2023
Q2 		$4.3M Buy
135,190
+92,234
+215% +$2.83M ﹤0.01% 2961
2023
Q1 		$1.05M Buy
42,956
+33,435
+351% +$981K ﹤0.01% 4909
2022
Q4 		$300K Buy
+9,521
New +$269K ﹤0.01% 7020
2022
Q2 		– Sell
-23,434
Closed -$665K – 11199
2022
Q1 		$820K Sell
23,434
-885
-4% -$25.8K ﹤0.01% 6535
2021
Q4 		$788K Sell
24,319
-1,343
-5% -$47.4K ﹤0.01% 6397
2021
Q3 		$757K Sell
25,662
-30,333
-54% -$852K ﹤0.01% 6480
2021
Q2 		$1.44M Buy
+55,995
New +$802K ﹤0.01% 5026

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Jane Street's CERE Position: Q3 2024 in Review

Jane Street sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 269,948 shares — an estimated $11M sold.

Jane Street first reported a position in CERE in Q2 2021 and held it in 10 quarters. The position peaked at $11M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Jane Street reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Jane Street sold 269,948 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $11M.
  • Jane Street first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • Jane Street's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $11M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Jane Street's 13F filing for Q3 2024, filed 15 Nov 2024.